Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

RARE PHOTOS: Looking into supernus pharmaceuticals s return on invested capital | Rare Historical Photos

According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Supernus Pharmaceuticals is not utilizing their capital as effectively as possible. Supernus Pharmaceuticals reached earnings of $21.56 million and sales of $148.46 million in Q3.

What Is ROIC?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.